Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

APRI 1.64 0.00 (0.00%)
price chart
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...
SAN DIEGO, May 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Vitaros´┐Ż in France by Laboratoires ...
Apricus Biosciences Is Executing Its Strategic Plans (APRI)
For the past few years, Apricus Biosciences, Inc. (NASDAQ:APRI) has attempted to turn its trajectory around and focus on a long-term strategy.
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
It's been almost six months since Vitaros was first launched by Apricus Biosciences (NASDAQ:APRI) in the UK, with follow-up launches in Germany, Sweden and Belgium.
Related articles »  
Apricus Biosciences Announces Corporate Update and First Quarter 2015 ...
SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2015 financial results ...
Apricus Biosciences to Present at the 27th Annual Roth Conference
SAN DIEGO, March 4, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will ...
Apricus Biosciences to Present at Two Investor Conferences in May
SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will ...
Building Value: Apricus Biosciences Report Issued by BrokerBank Securities, Inc.
NEW YORK, Jan. 9, 2015 /PRNewswire/ -- Apricus Biosciences, Inc. APRI, -3.80% is a pharmaceutical company that has developed alternative, fast-acting, treatments which appeal to large patient populations that struggle with unmet medical needs.
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.
Apricus Biosciences Inc (NASDAQ:APRI) Dashes After U.S. Patent Issuance For ...
Apricus Biosciences Inc (NASDAQ:APRI), a micro cap stock, jumped by as much as 9.02% to close at $1.33 in the previous trading session.
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2014 Results - Earnings ...
Greetings, and welcome to the Apricus Biosciences' Fourth Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast.
Apricus Biosciences Provides Corporate Update and 2014 Year-End Financial ...  GlobeNewswire (press release)